Royalty Pharma PLC (RPRX)
Stock Price Chart
Key Info
| Market Cap | 26.35B |
| Revenue (ttm) | 1.88B |
| Net Income (ttm) | n/a |
| Shares Out | 365.83M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Jul 14, 2020 |
| Last Price | $43.41 |
| Previous Close | $44.06 |
| Change ($) | -0.66 |
| Change (%) | -1.49% |
| Day's Open | 44.00 |
| Day's Range | 41.53 - 44.99 |
| Day's Volume | 1,983,624 |
| 52-Week Range | 41.53 - 56.50 |
More Stats
| Market Cap | 26.35B |
| Enterprise Value | 30.61B |
| Earnings Date (est) | n/a |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 365.83M |
| Float | n/a |
| EPS (basic) | n/a |
| EPS (diluted) | n/a |
| FCF / Share | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 2.01M |
| Short Ratio | 0.32 |
| Short % of Float | 0.76% |
| Beta | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | 14.01 |
| PB Ratio | 5.69 |
| Revenue | 1.88B |
| Operating Income | n/a |
| Net Income | n/a |
| Free Cash Flow | n/a |
| Net Cash | -4.26B |
| Net Cash / Share | -7.02 |
| Gross Margin | 150.70% |
| Operating Margin | n/a |
| Profit Margin | n/a |
| FCF Margin | n/a |
| ROA | n/a |
| ROE | n/a |
| ROIC | n/a |
Analyst Summary
Analyst Consensus: Overweight
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|---|---|---|
| Revenue | 1,814 | 1,795 | 1,598 |
| Revenue Growth | 1.08% | 12.33% | - |
| Gross Profit | 1,814 | 1,795 | 1,598 |
| Operating Income | 2,623 | 1,364 | 940 |
| Net Income | 2,349 | 1,378 | 1,210 |
| Operating Cash Flow | 1,667 | 1,618 | 1,418 |
| Capital Expenditures | -250 | - | - |
| Free Cash Flow | 1,417 | 1,618 | 1,418 |
| Cash & Equivalents | 793 | 2,386 | 0.00 |
| Total Debt | 6,238 | 6,519 | - |
| Net Cash / Debt | -5,445 | -4,133 | 0.00 |
| Assets | 12,450 | 11,370 | - |
| Liabilities | 6,308 | 6,818 | - |
| Book Value | 6,106 | 4,488 | - |
Company Profile
Company Details
| Full Name | Royalty Pharma PLC |
| Country | United States |
| CEO | Pablo Gerardo Legorreta |
Stock Information
| Ticker Symbol | RPRX |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Unique Identifier | NASDAQ: RPRX |
| IPO Date | June 16, 2020 |
Description
Royalty Pharma plc operates in the biopharmaceutical industry. The company operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry. It is involved in the identification, evaluation, and acquisition of royalties and royalty-related assets on various biopharmaceutical therapies. The company collaborates with innovators from academic institutions, research hospitals, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio includes royalties on approximately 45 commercial products and three development-stage product candidates. It has royalties on various therapeutic areas and drug classes, including Neulasta, Neupogen, Rituxan, Imbruvica, Trodelvy, Tazverik, and Xtandi in oncology; Lyrica in neuropathic pain; Biktarvy, Genvoya, Prezista, Symtuza, Truvada, and Atripla in HIV; Humira, Remicade, and Cimzia TNF inhibitors; Kalydeco, Orkambi, Symdeko, and Trikafta in cystic fibrosis; Tecfidera and Tysabri in multiple sclerosis; Emgality, Nurtec ODT (rimegepant), and vazegepant in migraine; and others. The company was founded in 1996 and is based in New York, New York.